Real Time Touch



new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)




Real Time Touch

Anthrogenesis Corporation patents


Recent patent applications related to Anthrogenesis Corporation. Anthrogenesis Corporation is listed as an Agent/Assignee. Note: Anthrogenesis Corporation may have other listings under different names/spellings. We're not affiliated with Anthrogenesis Corporation, we're just tracking patents.

ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "A" | Anthrogenesis Corporation-related inventors


Natural killer cells and uses thereof

Provided herein are methods of producing natural killer (NK) cells using a three-stage expansion and differentiation method with media comprising stem cell mobilizing factors. Also provided herein are methods of suppressing tumor cell proliferation using the NK cells and the NK cell populations produced by the three-stage methods described herein,... Anthrogenesis Corporation

Methods for isolation of platelets

Provided herein are methods for the isolation of platelets, for example, isolation of platelets from umbilical cord blood. In certain embodiments, presented herein are methods for preparation of platelet rich plasma. In one aspect, provided herein are methods for isolation of platelets from blood. In certain embodiments, presented herein are... Anthrogenesis Corporation

Composition for collecting and preserving placental stem cells and methods of using the composition

The present invention provides improved compositions and methods for the collection of stem cells from an organ, e.g., placenta. The invention provides a stem cell collection composition comprising an apoptosis inhibitor and, optionally, an enzyme such as a protease or mucolytic enzyme, vasodilator, necrosis inhibitor, oxygen-carrying perfluorocarbon, or an organ... Anthrogenesis Corporation

Treatment of diabetic foot ulcer using placental stem cells

Provided herein are methods of using tissue culture plastic-adherent placental cells, e.g. placental stem cells, in the treatment of diabetic foot ulcer (DFU).... Anthrogenesis Corporation

Cytotherapeutics, cytotherapeutic units and methods for treatments using them

The present invention provides cytotherapeutic units comprising predetermined numbers of selected types of potent cells. Assurance of the nature and identities of such cells is achieved through assay and certification of said numbers and identities. Therapeutic modalities are provided. Libraries of cell preparations with assayed and preferably certified populations are... Anthrogenesis Corporation

Methods for quantifying particulates in cell culture

Provided are methods for quantifying and/or detecting sub-visible particulates in cell cultures. Specifically, the methods comprise a step of breaking down, e.g., lysing, cells in a cell culture. The methods can further comprising filtering the cell culture through a filter. Further provided are methods of quantifying sub-visible particulates that do... Anthrogenesis Corporation

Placenta-derived adherent cell exosomes and uses thereof

Provided herein are compositions of placenta-derived adherent cell exosomes and methods of making and using the same. In one aspect, provided herein are compositions comprising exosomes produced by and/or derived from placental cells, e.g., placenta-derived adherent cells. In certain embodiments, the exosomes provided herein are produced by placenta-derived adherent cells... Anthrogenesis Corporation

Method of producing erythrocytes

Provided herein are methods of producing erythrocytes from hematopoietic cells, particularly hematopoietic cells from placental perfusate in combination with hematopoietic cells from umbilical cord blood, wherein the method results in accelerated expansion and differentiation of the hematopoietic cells to more efficiently produce administrable erythrocytes. Further provided herein is a bioreactor... Anthrogenesis Corporation

Placental stem cells derived from post-partum mammalian placenta, and uses and methods of treatment using said cells

The present invention provides compositions and methods of using placental stem cells that originate from a post-partum placenta with conventional cord blood compositions or other stem or progenitor cells. The placental stem cells can be used alone or in a mixture with other stem cell populations. In accordance with the... Anthrogenesis Corporation

Methods of improving vector transduction efficiency into t lymphocytes

Provided herein are methods for enhancing the transduction efficiency of vectors into cells, e.g., primary human T lymphocytes.... Anthrogenesis Corporation

Organoids comprising decellularized and repopulated placental vascular scaffold

Provided herein are organoids comprising decellularized placental vascular scaffold comprising, or consisting of, a decellularized placental vascular scaffold, and methods of making and using the same.... Anthrogenesis Corporation

Human placental collagen compositions, and methods of making and using the same

The present invention provides compositions comprising human placental telopeptide collagen, methods of preparing the compositions, methods of their use and kits comprising the compositions. The compositions, kits and methods are useful, for example, for augmenting or replacing tissue of a mammal.... Anthrogenesis Corporation

Renovation and repopulation of decellularized tissues and cadaveric organs by stem cells

A method of manufacturing a tissue matrix for implantation into a patient is disclosed. The method sets forth collecting embryonic stem cells from a placenta which has been treated to remove residual cord blood and seeding the collected stem cells onto or into a tissue matrix. The seeded tissue matrix... Anthrogenesis Corporation

Methods and compositions for treatment of bone defects with placental cell populations

Provided herein are methods of using adherent placental stem cells and placental stem cell populations, and methods of culturing, proliferating and expanding the same. Also provided herein are methods of differentiating the placental stem cells. Further provided herein are methods of using the placental stem cells to formulate implantable or... Anthrogenesis Corporation

Extracellular matrix compositions

Provided herein are placental extracellular matrix (ECM) compositions and methods of making the same. Also provided herein are uses of the placental ECM compositions provided herein.... Anthrogenesis Corporation

Treatment of conditions and complications in infants

Provided herein are compositions and methods for treating one or more disorders or conditions in infants, including premature infants, by administering to such infants umbilical cord blood or cells obtained from umbilical cord blood and, optionally, cells obtained from placental perfusate, placental stem cells and/or blood additives. Also provided herein... Anthrogenesis Corporation

Treatment of inflammatory diseases using placental stem cells

Provided herein are methods of treatment of individuals having an immune-related disease, disorder or condition, for example, inflammatory bowel disease, graft-versus-host disease, multiple sclerosis, rheumatoid arthritis, psoriasis, lupus erythematosus, diabetes, mycosis fungoides (Alibert-Bazin syndrome), or scleroderma using placental stem cells or umbilical cord stem cells.... Anthrogenesis Corporation

Modulation of stem cell and progenitor cell differentiation, assays, and uses thereof

The present invention relates to methods of modulating mammalian stem cell and progenitor cell differentiation. The methods of the invention can be employed to regulate and control the differentiation and maturation of mammalian, particularly human stem cells along specific cell and tissue lineages. The methods of the invention relate to... Anthrogenesis Corporation

Enhancement of placental stem cell potency using modulatory rna molecules

Provided herein are methods of producing enhanced placental stem cells by modulatory RNA molecules. Also provided herein are methods of using enhanced placental stem cells, for example, to treat individuals having a disease, disorder or condition caused by, or relating to, an unwanted or harmful immune response. Further provided herein... Anthrogenesis Corporation

Methods of generating natural killer cells

Provided herein are methods of producing natural killer cells using a two-step expansion and differentiation method. Also provided herein are methods of suppressing tumor cell proliferation, of treating individuals having cancer or a viral infection, comprising administering the NK cells produced by the method to an individual having the cancer... Anthrogenesis Corporation








ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Anthrogenesis Corporation in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Anthrogenesis Corporation with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###